Increasing Medical Marijuana And Cannabidiol Research

The order directs rapid federal action to reschedule marijuana, expand medical research, and strengthen oversight of CBD products, aiming to close gaps in safety, efficacy, and patient guidance.

What the order does ​

• Directs the Attorney General to expedite rescheduling marijuana to Schedule III.
• Calls for legislative work to update the legal definition of hemp-derived cannabinoid products.
• Mandates creation of a regulatory framework for hemp-derived cannabinoids, including THC limits and CBD-THC ratio guidelines.
• Orders federal health agencies to develop real-world evidence research methods to inform standards of care and improve access.

Who it affects ​

• Patients using medical marijuana or CBD products.
• Healthcare providers.
• Manufacturers and sellers of cannabinoid products.
• Federal agencies and regulators.

Context ​

The action follows scientific consensus and state-level legalization trends, responding to longstanding research and policy delays.